Current opinion in anaesthesiology, 26(4), 404-408 (2013-06-08)
To evaluate the most recent publications in the long-lived debate over the use of etomidate in critically ill septic and trauma patients. Virtually without controversy is the hemodynamic stability after its use for induction of anesthesia on the one hand
The Annals of pharmacotherapy, 44(7-8), 1307-1313 (2010-06-10)
To evaluate the risk of adrenal insufficiency following a single dose of etomidate in patients with suspected sepsis requiring rapid sequence intubation. A literature search was conducted using PubMed, MEDLINE, EMBASE, and International Pharmaceutical Abstracts from the dates of database
Current pharmaceutical design, 18(38), 6253-6256 (2012-07-06)
Etomidate is a well established intravenous anaesthetic agent which has been widely used. Recognised limitations of the agent include adrenocortical suppression, myoclonus and post-operative nausea and vomiting, PONV. MOC-etomidate, carboetomidate and MOC-carboetomidate are novel etomidate derivatives. Their preclinical data and
Critical care medicine, 40(11), 2945-2953 (2012-09-14)
To evaluate the effects of single-dose etomidate on the adrenal axis and mortality in patients with severe sepsis and septic shock. A systematic review of randomized controlled trials and observational studies with meta-analysis. Literature search of EMBASE, Medline, Cochrane Database
European journal of anaesthesiology, 29(11), 506-510 (2012-08-22)
Etomidate is used to induce anaesthesia in critically ill patients in many environments, including pre-hospital care, in the emergency and critical care departments and in the operating theatre. It has a favourable cardiovascular profile, but its use has courted controversy
